HK Stock Market Move | SUNSHINE PHARMA (06887) rose more than 4% in the final hour of trading. The first generic version of Fingolimod Hydrochloride Capsules was approved by the National Medical Products Administration for listing.

SUNSHINE PHARMA (06887) rose more than 4% in the final trading session, rising by 4.38% to HKD 47.7 at the time of reporting, with a turnover of HKD 149.824 million. On the news front, on October 11th, the official website of the China National Medical Products Administration announced that Guangdong SUNSHINE PHARMA's hydrochloride fenogomide capsules, classified under chemical drug registration, have been approved for listing, becoming the first generic drug in China and also the company's first oral immunosuppressant. It is reported that fenogomide is the world's first oral drug for the treatment of multiple sclerosis (MS), jointly developed by Novartis and Mitsubishi Pharma of Japan. It was approved for listing in the United States in 2010, with global sales exceeding $3 billion from 2016 to 2020. CMSC released a research report stating that SUNSHINE PHARMA, as the first Chinese stock listed through a merger and introduction, has built an integrated research, production, and sales platform for innovative pharmaceutical companies through mergers and acquisitions. The company's research and development focus on three major areas: anti-infection, chronic disease (metabolism), and oncology, with a rich reserve of research and development pipelines and rapid production of listed products, marking the start of a new era of global innovation. The firm is optimistic about the company's development of innovative pipelines, initiating coverage for the first time, and giving a "strong buy" investment rating.